Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer
Open Access
- 1 April 2003
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 88 (7) , 1017-1024
Abstract
This study was designed to evaluate the benefits of neoadjuvant chemotherapy prior to chemoradiation and surgery in patients with locally advanced rectal cancer. Patients with previously untreated primary rectal cancer, reviewed in a multidisciplinary meeting and considered to have locally advanced disease on the basis of physical examination and imaging (MRI+CT n=30, CT alone n=6), were recruited. Patients received protracted venous infusion 5-FU (300 mg m−2 day−1 for 12 weeks) with mitomycin C (MMC) (7 mg m−2 i.v. bolus every 6 weeks). Starting on week 13, 5-FU was reduced to 200 mg m−2 day−1 and concomitant pelvic radiotherapy 45 Gy in 25 fractions was commenced followed by 5.4–9 Gy boost to tumour bed. Surgery was planned 6 weeks after chemoradiation. Postoperatively, patients received 12 weeks of MMC and 5-FU at the same preoperative doses. Between January 99 and August 01, 36 eligible patients were recruited. Median age was 63 years (range=40–85). Following neoadjuvant chemotherapy, radiological tumour response was 27.8% (one CR and nine PRs) and no patient had progressive disease. In addition, 65% of patients had a symptomatic response including improvement in diarrhoea/constipation (59%), reduced rectal bleeding (60%) and diminished pelvic pain/tenesmus (78%). Following chemoradiation, tumour regression occurred in 80.6% (six CRs and 23 PRs; 95% CI=64–91.8%) and only one patient still had an inoperable tumour. R0 resection was achieved in 28 patients (82%). When compared with initial clinical staging, the pathological downstaging rate in T and/or N stage was 73.5% and pathological CR was found in one patient. Neoadjuvant systemic chemotherapy as a prelude to synchronous chemoradiation can be administered with negligible risk of disease progression and produces considerable symptomatic response with associated tumour regression.Keywords
This publication has 43 references indexed in Scilit:
- Local recurrence after mesorectal excision for rectal cancerEuropean Journal of Surgical Oncology, 2002
- Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancerBritish Journal of Surgery, 2002
- Assessing The Predictive Value of Clinical Complete Response To Neoadjuvant Therapy for Rectal Cancer: An Analysis of 488 PatientsJournal of the American College of Surgeons, 2002
- Neoadjuvant Chemoradiation for Rectal Cancer: Analysis of Clinical Outcomes From a 13-Year Institutional ExperienceAnnals of Surgery, 2001
- Improved Survival and Reduction in Local Failure Rates After Preoperative RadiotherapyAnnals of Surgery, 1999
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998
- Rectal CancerArchives of Surgery, 1998
- Time-dependent interactions between 5-fluorouracil and mitomycin C on a human colon carcinoma cell line, HCT-8, in vitroEuropean Journal of Cancer and Clinical Oncology, 1989
- LOCAL RECURRENCE OF RECTAL ADENOCARCINOMA DUE TO INADEQUATE SURGICAL RESECTIONThe Lancet, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958